Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

Abiraterone acetate plus prednisone and enzalutamide ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

NICE is unable to make a recommendation about the use in the NHS of niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is ...